Protection of Omicron Bivalent Vaccine, Previous Infection, and Their Induced Neutralizing Antibodies Against Symptomatic Infection With Omicron XBB.1.16 and EG.5.1
In the era when the Omicron XBB vaccine was unavailable, the Omicron BA bivalent vaccine did not confer the neutralizing activity and protection against Omicron XBB.1.16 and EG.5.1 symptomatic infection. The previous infection afforded neutralizing titers and protection against symptomatic infection with these variants.
Authors
- Shohei Yamamoto (ORCID: https://orcid.org/0000-0001-6503-8577)
- Junko S. Takeuchi (ORCID: https://orcid.org/0000-0002-4844-9013)
- Tetsuya Mizoue (ORCID: https://orcid.org/0000-0002-1198-2228)
- Nobuyoshi Aoyanagi (ORCID: https://orcid.org/0000-0002-8037-6440)
- Wataru Sugiura (ORCID: https://orcid.org/0000-0002-3132-0918)
- Takashi Nemoto
- Yusuke Oshiro
- Natsumi Inamura
- Kenji Maeda (ORCID: https://orcid.org/0000-0002-9424-1491)
- Maki Konishi
- Kaori Okudera
- Norio Ohmagari (ORCID: https://orcid.org/0000-0002-4622-8970)
- Haruhito Sugiyama (ORCID: https://orcid.org/0000-0002-7849-1327)
- Kouki Matsuda (ORCID: https://orcid.org/0000-0002-4757-7128)
- Tomofumi Tan
- Kumi Horii
Institutions
- Kagoshima University (JP)
- National Center for Global Health and Medicine (JP)
- Center for Global Health (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1093/ofid/ofae519
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Abbott Japan
- National Center for Global Health and Medicine
- Japan Health Research Promotion Bureau